Roivant Shares Rise After Strong Phase 3 Results for Brepocitinib in Uveitis
Positive CLARITY Phase 3 data for brepocitinib in uveitis lifts Roivant stock. Median time to treatment failure exceeded 48 weeks.
Already have an account? Sign in.